FK949E

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Bipolar Depression

Conditions

Bipolar Depression

Trial Timeline

Feb 18, 2015 → Feb 6, 2016

NCT ID

NCT02362412

About FK949E

FK949E is a phase 3 stage product being developed by Astellas Pharma for Bipolar Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT02362412. Target conditions include Bipolar Depression.

What happened to similar drugs?

20 of 20 similar drugs in Bipolar Depression were approved

Approved (20) Terminated (3) Active (0)

✅Olanzapine + PlaceboEli LillyApproved

✅OlanzapineEli LillyApproved

✅olanzapine + divalproex sodium + placeboEli LillyApproved

✅olanzapine + risperidoneEli LillyApproved

✅Topiramate + PlaceboEli LillyApproved

✅Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02362412	Phase 3	Completed	Feb 18, 2015	Feb 6, 2016	Bipolar Depression
NCT01737268	Phase 3	Completed	Oct 29, 2012	Jun 29, 2016	Bipolar Disorder
NCT01919008	Phase 1	Completed	Mar 26, 2012	Jun 22, 2012	Major Depressive Disorder
NCT01924520	Phase 1	Completed	Nov 1, 2010	May 1, 2011	Major Depressive Disorder
NCT01903200	Phase 1	Completed	Feb 1, 2010	Sep 1, 2011	Major Depressive Disorder Patients
NCT01871987	Phase 1	Completed	Jun 1, 2009	Aug 1, 2009	Healthy
NCT01871974	Phase 1	Completed	May 1, 2009	Mar 1, 2010	Major Depressive Disorder Patients

Competing Products

20 competing products in Bipolar Depression

See all competitors

Product	Company	Stage	Hype Score
Olanzapine	Eli Lilly	Phase 3	32
Valproate + Lithium + Risperidone + Olanzapine	Eli Lilly	Phase 3	40
Olanzapine + Placebo	Eli Lilly	Approved	43
FK949E	Astellas Pharma	Phase 3	40
FK949E + Placebo	Astellas Pharma	Phase 2/3	38
Escitalopram + Bupropion XL	Lupin Limited	Phase 3	32
Olanzapine	Eli Lilly	Approved	43
Olanzapine Hydrochloride + Lithium Carbonate	Eli Lilly	Phase 3	40
olanzapine + lithium + valproate + carbamazepine	Eli Lilly	Phase 3	40
Olanzapine	Eli Lilly	Approved	43
Olanzapine	Eli Lilly	Phase 3	40
LY2979165 + Placebo	Eli Lilly	Phase 1	29
olanzapine + divalproex sodium + placebo	Eli Lilly	Approved	43
olanzapine + risperidone	Eli Lilly	Approved	43
LY2979165 + placebo	Eli Lilly	Phase 1	29
Topiramate + Placebo	Eli Lilly	Approved	43
olanzapine	Eli Lilly	Phase 3	40
Olanzapine + Placebo	Eli Lilly	Phase 3	40
Brenipatide + Placebo	Eli Lilly	Phase 2	42
Olanzapine Fluoxetine Combination (OFC) + Placebo	Eli Lilly	Approved	43